Active, not recruitingNCT04461639

Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent Bleeding

Studying Hemophilia

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Bayer
Intervention: Damoctocog alfa pegol (Jivi, BAY94-9027)(drug)
Enrollment: 62 enrolled
Eligibility: 12 years · All sexes
Timeline: 2021 – 2028

Study locations (6)

Many Locations, Multiple Locations, Austria
Many Locations, Multiple Locations, Germany
Many Locations, Multiple Locations, Greece
Many Locations, Multiple Locations, Italy
Many Locations, Multiple Locations, Slovenia
Many Locations, Multiple Locations, Spain

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04461639 on ClinicalTrials.gov

Other trials for Hemophilia

Additional recruiting or active studies for the same condition.

See all trials for Hemophilia →

← Back to all trials